-dioxygenase

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Yousef Zakharia, Robert R McWilliams, Olivier Rixe, Joseph Drabick, Montaser F Shaheen, Kenneth F Grossmann, Ravindra Kolhe, Rafal Pacholczyk, Ramses Sadek, Lucinda L Tennant, Christopher M Smith, Eugene P Kennedy, Charles J Link Jr, Nicholas N Vahanian, Jiayi Yu, Steven S Shen, Erik L Brincks, Gabriela R Rossi, David Munn, Mohammed Milhem

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002057; DOI: 10.1136/jitc-2020-002057
GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
Matteo Caforio, Cristina Sorino, Ignazio Caruana, Gerrit Weber, Antonio Camera, Loredana Cifaldi, Biagio De Angelis, Francesca Del Bufalo, Alessia Vitale, Bianca Maria Goffredo, Rita De Vito, Doriana Fruci, Concetta Quintarelli, Maurizio Fanciulli, Franco Locatelli, Valentina Folgiero

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001502; DOI: 10.1136/jitc-2020-001502

Main menu